BFM
PMN icon

Boothbay Fund Management’s ProMIS Neurosciences PMN Stock Holding History

Boothbay Fund Management’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$817K Buy
62,078
+46,035
+287% +$500K 0.01% 1224
2026
Q1 		$204K Buy
+16,043
New +$239K ﹤0.01% 1777

Other funds holding PMN

JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Boothbay Fund Management's PMN Position: Q2 2026 in Review

Boothbay Fund Management increased its ProMIS Neurosciences (PMN) stake by 287% in Q2 2026, buying an estimated $500K and bringing the position to 62,078 shares worth $817K. The position accounts for 0.01% of the portfolio, ranked #1224.

Boothbay Fund Management first reported a position in PMN in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold PMN as of Q2 2026.

  • Boothbay Fund Management held 62,078 shares of ProMIS Neurosciences worth $817K as of Q2 2026.
  • Boothbay Fund Management bought 46,035 ProMIS Neurosciences shares in Q2 2026, an estimated $500K.
  • ProMIS Neurosciences made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1224 holding.
  • Boothbay Fund Management first reported a position in ProMIS Neurosciences in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.